Forschung am Lehrstuhl für Medizinische Biometrie

Laufende klinische Studien

Studie (Akronym) & Art der StudieSponsor/ AuftraggeberStudienleitung/ SDPMitarbeiter (IBE)Status
APART:
Wirksamkeit des Affolter-Modells® bei Patienten mit Ataxie nach Schlaganfall: randomisierte, kontrollierte, verblindete klinische Studie im Parallelgruppendesign mit Messwiederholungen
Universität AugsburgProf. Dr. E. Grill
Prof. Dr. A. Bender
Dr. R. StroblProtokollentwicklung
CML Absetzregister:
Wissenschaftliches Register zur prospektiven Erfassung der therapiefreien Remission bei chronischer myeloischer Leukämie mit dem Ziel der Erforschung prognostischer Faktoren
Universität HeidelbergProf. Dr. S. SaußeleProf. Dr. M. Pfirrmann
A. Albeer
Rekrutierung
ESTIMATION: Efficacy of asciminib in chronic phase CML patients with T315I mutationsFriedrich-Schiller-Universität JenaProf. Dr. T. ErnstProf. Dr. M. Pfirrmann
T. Brenninger-Lang
Protokollentwicklung
PROTAGORAS: PROTamine Application in patients underGOing tRAnScatheter aortic valve replacement (PROTAGORAS)Klinikum der
LMU
Prof. Dr. S. Massberg
Prof. Dr. L. Weckbach
PD Dr. M. Lauseker-Hao
Dr. Y. Xu
Rekrutierung
ARTIST: Risk-adapted frontline treatment with AsciminibFriedrich-Schiller-Universität JenaProf. Dr. T. ErnstProf. Dr. M. Pfirrmann
A. Albeer
Protokollentwicklung
ECWM-2: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s MacroglobulinemiaUniklinik UlmProf. Dr. C. BuskeProf. Dr. E. Hoster
K. Gutmair
Auswertung
PLATO: Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients: a phase II trial of the European MCL NetworkKlinikum der
LMU
Dr. C. SchmidtProf. Dr. E. Hoster
L. Jiang
Rekrutierung
EEN-RICH: A randomized, double-blind, placebo-controlled, phase I/II trial of multi-donor fecal microbiota transfer for maintenance of Remission after Induction treatment with Exclusive Enteral Nutrition (EEN) in CroHn’s disease (EEN-RICH study)Klinikum der
LMU - Dr. von Haunersches Kinderspital
PD Dr. T. SchwerdProf. Dr. E. Hoster
L. Jiang
Rekrutierung
VIWA-1: Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia (VIWA-1) – a multicenter, randomized, explorative open label phase II international studyUniklinik UlmProf. Dr. C. BuskeProf. Dr. E. HosterRekrutierung
COUP-1: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients – a multicenter open label single-arm phase II studyUniklinik UlmProf. Dr. C. BuskeProf. Dr. E. HosterRekrutierung
PRiSMA: Pädiatrisches Register für Schlaganfall als multidisziplinäre Ausgangsplattform fokussierter Forschung und VersorgungKlinikum der
LMU - Dr. von Haunersches Kinderspital
PD Dr. L. GerstlPD Dr. M. Lauseker-Hao
J. Fusiak
Rekrutierung
PRIDE: PRotective VEGF Inhibition for Isotoxic Dose Escalation in GlioblastomaKlinikum der
LMU
Prof. Dr. M. NiyaziProf. Dr. U. MansmannRekrutierung
CARMAN: Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B): a randomized phase II studyKlinikum der
LMU - Med III
Prof. Dr. M. DreylingProf. Dr. E. Hoster
L. Jiang
Rekrutierung
MASPAC: MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) – a Randomized, Controlled Clinical StudyKlinikum der
LMU
Prof. Dr. M. NiyaziProf. Dr. U. Mansmann
M. Müller
Dr. Y. Xu
Auswertung
EPIDAURUS: Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary syndrome undergoing percutaneoUS coronary interventionKlinikum der
LMU
PD Dr. K. RizasProf. Dr. U. MansmannRekrutierung
PROFIL: Effect of propionate supplementation as an anti-inflammation approach on neurofilaments in patients with corticobasal syndrome (CBS): Double-blind, randomized, placebo-controlled, parallel-group, phase II studyKlinikum der
LMU - DSGZ
Prof. Dr. J. LevinProf. Dr. U. MansmannRekrutierung
MCL Elderly III: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapyUniklinik MainzProf. Dr. G. HessProf. Dr. E. Hoster
L. Jiang
Rekrutierung
ALTERNATIVE-C: A prospective multicenter phase 2 study of the chemotherapy-free combination of the intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor Copanlisib in combination with Obinutuzumab in patients with previously untreated follicular lymphoma (FL) and a high tumor burdenKlinikum der
LMU - Med III
Dr. C. SchmidtProf. Dr. E. Hoster
Dr. V. Jurinovic
Auswertung
CZAR-1: Randomisierte Phase-3-Studie des European Consortium for Waldenström´s Macroglobulinemia zur Behandlung des Morbus Waldenström mit Ibrutinib mit oder ohne CarfilzomibUniklinik UlmProf. Dr. C. BuskeProf. Dr. E. HosterRekrutierung
XVIR-01: Single center, open-label, phase I, dose finding and safety study on the oncolytic adenovirus XVir-N-31 in patients with recurrent glioblastoma (XVIR-01)Goethe
-Universität
Frankfurt
Prof. Dr. J. P. SteinbachPD Dr. M. Lauseker-HaoProtokollentwicklung
PyloResPres: Pylorus resection versus pylorus preservation in pancreatoduodenectomy: A multicenter surgical registry-based randomized active-controlled trial (RRCT) from the German DGAV StuDoQ|Pancreas RegistryKlinikum der
LMU
Prof. Dr. J. WernerDr. A. CrispinAuswertung
PONTrack: Prospective, non-randomised, open-label, multicentre phase II trial of patients with CML treated with Ponatinib in order to assess MR4 achievement after 2 years of treatmentUniversität
Heidelberg
Prof. Dr. S. SaußeleProf. Dr. M. Pfirrmann
A. Albeer
Auswertung
FASCINATION: Prospective, non-randomised, open-label, multicentre phase II trial of patients with de novo BCR-ABL1 positive CML in chronic phase, treated with a combination of an established TKI and asciminib in order to assess impact on deep molecular responseFriedrich-Schiller-Universität JenaProf. Dr. T. ErnstProf. Dr. M. Pfirrmann
T. Brenninger-Lang
Rekrutierung
BlastCrisis: European CML blast crisis registry for patients with CML in blast crisisFriedrich-Schiller-Universität JenaDr. C. Fabisch
PD Dr. A. Brioli
PD Dr. M. Lauseker-Hao
PD Dr. M. Lauseker-HaoAuswertung
TRACE: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific CD4+ and CD8+ T cells against AdV, CMV and EBV: A Phase III, prospective multicentre clinical trial. Multivirus-specific T-cell transfer post SCT vs AdV, CMV and EBV infectionsAlbert-Ludwigs-Universität FreiburgProf. Dr. T. FeuchtingerProf. Dr. M. PfirrmannRekrutierung
MARTHA: Milk Against Respiratory Tract Infections and AsthmaKlinikum der LMU - Dr. von Haunersches KinderspitalProf. Dr. E. von MutiusProf. Dr. U. MansmannRekrutierung
GABe2016: First line therapy of advanced stage follicular lymphoma in patients < 60 years not eligible for standard immunochemotherapy and all patients ≥ 60 years - Prospective randomized evaluation of single agent GA101 versus GA101 plus Bendamustine followed by GA101Klinikum der
LMU
Prof. Dr. C. BuskeProf. Dr. E. Hoster
Dr. V. Jurinovic
Auswertung
RESIST: Optimization of individualized therapy for CRCs with secondary RESISTance towards anti-EGFR targeted therapy using an avatar model (Colon-Resist-Net)Klinikum der
LMU
Prof. Dr. S. StintzingProf. Dr. U. MansmannRekrutierung
NAUT: Multicenter Prospective Trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of Nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd timeUniversität
Heidelberg
Prof. Dr. S. SaußeleProf. Dr. M. Pfirrmann
A. Albeer
Rekrutierung
HyperTET: Trabectedin with Regional Hyperthermia as second line treatment for patients with advanced soft-tissue sarcomaKlinikum der
LMU - Med III/ Hyperthermie
Prof. Dr. R. IsselsProf. Dr. U. Mansmann
Dr. Y. Xu
Auswertung
TRIANGLE: Autologous transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle cell lymphoma –a randomized European mcl network trialKlinikum der
LMU - Med III
Prof. Dr. M. DreylingProf. Dr. E. Hoster
L. Jiang
Auswertung